drug · small molecule
dapagliflozin propanediol
Marketedupdated 6mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for heart failure and type 2 diabetes mellitus and 4 investigational indications.
indications
investigational
Type 2 Diabetes
targets
Sodium/glucose cotransporter 2
all catalysts(0)
nothing on the calendar yet
Trials studying dapagliflozin propanediol
- phase4Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
- N/AThe DAPA-MEMRI Trial
- phase3DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
- phase3Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
- phase4Dapagliflozin Treatment in Type 2 Diabetes
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 18, 2027
90 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (54)
- Oct 1, 2041patentUS 12213988*PED
- Oct 1, 2041patentUS 12409186*PED
- Apr 1, 2041method-of-use (U-4140)US 12213988
- Apr 1, 2041method-of-use (U-4140)US 12409186
- Sep 9, 2040patentUS 10973836*PED
- Sep 9, 2040patentUS 11903955*PED
- Mar 9, 2040method-of-use (U-3127)US 10973836
- Mar 9, 2040method-of-use (U-3825)US 11903955
- Jan 18, 2040patentUS 11826376*PED
- Jan 18, 2040patentUS 12472194*PED
- Jul 18, 2039method-of-use (U-3766)US 11826376
- Jul 18, 2039method-of-use (U-4346)US 12472194
- Nov 26, 2030patentUS 8685934*PED4.0y
- Nov 26, 2030patentUS 8685934*PED4.0y
- Jul 18, 2030patentUS 8721615*PED3.7y
- Jul 18, 2030patentUS 8721615*PED3.7y
- Jun 16, 2030patentUS 7919598*PED3.6y
- Jun 16, 2030patentUS 7919598*PED3.6y
- May 26, 2030method-of-use (U-1522)US 86859343.5y
- May 26, 2030method-of-use (U-1522)US 86859343.5y
- Dec 16, 2029compositionUS 79195983.1y
- Dec 16, 2029compositionUS 79195983.1y
- Feb 19, 2029patentUS 7851502*PED2.3y
- Feb 19, 2029patentUS 7851502*PED2.3y
- Sep 21, 2028patentUS 8221786*PED1.8y
- Sep 21, 2028patentUS 8221786*PED1.8y
- Sep 21, 2028patentUS 8361972*PED1.8y
- Sep 21, 2028patentUS 8361972*PED1.8y
- Sep 21, 2028patentUS 8716251*PED1.8y
- Sep 21, 2028patentUS 8716251*PED1.8y
- Aug 19, 2028formulationUS 78515021.7y
- Aug 19, 2028formulationUS 78515021.7y
- Mar 21, 2028formulationUS 82217861.3y
- Mar 21, 2028formulationUS 82217861.3y
- Mar 21, 2028method-of-use (U-493)US 83619721.3y
- Mar 21, 2028method-of-use (U-493)US 83619721.3y
- Mar 21, 2028formulationUS 87162511.3y
- Mar 21, 2028formulationUS 87162511.3y
- Dec 20, 2027patentUS 8501698*PED1.1y
- Dec 20, 2027patentUS 8501698*PED1.1y
- Jun 20, 2027formulationUS 8501698212d
- Jun 20, 2027formulationUS 8501698212d
- Feb 18, 2027patentUS 8329648*PED90d
- Feb 18, 2027patentUS 8329648*PED90d
- Feb 18, 2027patentUS 8906851*PED90d
- Feb 18, 2027patentUS 8906851*PED90d
- Aug 18, 2026method-of-use (U-2213)US 8329648
- Aug 18, 2026method-of-use (U-2212)US 8329648
- Aug 18, 2026method-of-use (U-2139)US 8906851
- Aug 18, 2026method-of-use (U-2139)US 8906851
- Apr 4, 2026patentUS 6515117*PED
- Apr 4, 2026patentUS 6515117*PED
- Oct 4, 2025compositionUS 6515117
- Oct 4, 2025compositionUS 6515117
FDA exclusivities (8)
- Dec 12, 2027PEDPediatric (6mo bonus)1.1y
- Dec 12, 2027PEDPediatric (6mo bonus)1.1y
- Jun 12, 2027NPPNew Product (3y)204d
- Jun 12, 2027NPPNew Product (3y)204d
- Nov 8, 2026PEDPediatric (6mo bonus)
- Nov 8, 2026PEDPediatric (6mo bonus)
- May 8, 2026M-298Method (3y)
- May 8, 2026M-298Method (3y)
News(6)
- AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging marketsAstraZeneca’s leadership hinted at where the cost cuts and job losses from the company’s new restructuring program might fall on a call with journalists Friday. “We are losing patent protection for…endpoints · 20d ago
- STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and moreAstraZeneca has launched a three-year cost-cutting program that aims to slice off $1.5 billion a year, with the savings reinvested in R&D.stat · 20d ago
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
- After PCOS became PMOS, there’s hope for new awareness among Black and Latina womenGrowing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis.stat · 3mo ago
- AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failureAstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…biospace · 3mo ago
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.biospace · 4mo ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that